Cholera - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Cholera - Pipeline Review, H1 2019’, provides an overview of the Cholera pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cholera and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cholera

- The report reviews pipeline therapeutics for Cholera by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Cholera therapeutics and enlists all their major and minor projects

- The report assesses Cholera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Cholera

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cholera

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akthelia Pharmaceuticals Ltd

Beijing Minhai Biotechnology Co Ltd

Napo Pharmaceuticals Inc

Akthelia Pharmaceuticals Ltd

Beijing Minhai Biotechnology Co Ltd

Napo Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cholera - Overview

Cholera - Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cholera - Overview

Cholera - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cholera - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cholera - Companies Involved in Therapeutics Development

Akthelia Pharmaceuticals Ltd

Beijing Minhai Biotechnology Co Ltd

Napo Pharmaceuticals Inc

Cholera - Drug Profiles

AKT-10082 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholera (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholera (whole cell) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholera [serotypes O1 + O139] (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholera [strain O1/El/Tor/Ogawa] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholera vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cholera vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cholvax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crofelemer DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gram-negative bacterial infections vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMSUTMR-1501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cholera - Dormant Projects

Cholera - Discontinued Products

Cholera - Product Development Milestones

Featured News & Press Releases

Jun 13, 2018: Fast-acting Cholera Vaccine Could Curb Outbreaks

Apr 27, 2016: Hilleman Laboratories Provides Phase I/II Update on Cholera Vaccine

Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cholera, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Tables

Number of Products under Development for Cholera, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Cholera - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2019

Cholera - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2019

Cholera - Pipeline by Napo Pharmaceuticals Inc, H1 2019

Cholera - Dormant Projects, H1 2019

Cholera - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Cholera, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Figures

Number of Products under Development for Cholera, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports